# US 2024/0197977 A1 · Improved immune response and decreased immunoparalysis with immunomodulating treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197977 A1
- Document ID: US20240197977A1
- Status: Published application
- Kind: A1
- Application number: 17/919,053
- Filed: 2021-04-14
- Published: 2024-06-20
- Earliest claimed: 2020-04-14
- Assignees: CytoSorbents Corporation
- Applicants: Cytosorbents, Inc.
- Inventors: Phillip P CHAN; Vincent J. CAPPONI; Thomas D. Golobish; Wei-Tai YOUNG; Ophir ORTIZ; Ritu TRIPATHI
- Web page: https://patentgrep.com/patent/US20240197977A1

## CPC

- A61M 1/3679: {by absorption (A61M1/3675 takes precedence)}
- A61K 31/765: Polymers containing oxygen
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/04: Immunostimulants
- A61P 39/00: General protective or antinoxious agents
- B01J 20/267: {Cross-linked polymers}
- B01J 20/28073: {being in the range 0.5-1.0 ml/g}
- B01J 20/28076: {being more than 1.0 ml/g}
- B01J 20/28083: {being in the range 2-50 nm, i.e. mesopores}
- B01J 20/28085: {being more than 50 nm, i.e. macropores}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS

## Abstract

The invention concerns methods of treating immunoparalysis by the attenuation via removal of inflammatory mediators and/or checkpoint inhibitor proteins in a subject, comprising treating a subject with a therapeutically effective amount of porous biocompatible polymer sorbent comprising a range of pore diameters between about 50 Å to about 3000 Å and a pore volume between about 0.5 cc/g to about 3.0 cc/g dry polymer; or comprising a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5.0 cc/g dry polymer.

## Claims

### Claim 1

A method of treating immune suppression, anergy, or immunoparalysis by the attenuation via removal of inflammatory, and/or anti-inflammatory mediators, and/or checkpoint inhibitor proteins in a subject, comprising treating a subject with a therapeutically effective amount of porous biocompatible polymer sorbent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 3000 Å and a pore volume between about 0.5 cc/g to about 3 cc/g dry polymer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5 cc/g dry polymer.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the sorbent is administered extracorporeally.

### Claim 5 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the sorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, orally, rectally, topically, or nasally.

### Claim 6 (depends on 3)

The method of claim 3, wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 1,000 Å to 10,000 Å (pore diameter) of the sorbent is smaller than 2:1.

### Claim 7

The method of any one of the preceding claims, wherein the sorbent is produced using at least one crosslinking agent and at least one monomer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the monomer comprises one or more of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.

### Claim 9 (depends on 7, 8)

The method of claim 7 or claim 8, wherein the crosslinking agent comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythrital dimethacrylates, pentaerythrital trimethacrylates, pentaerythrital, tetramethacrylates, pentaerythritol diacrylates, pentaerythritol triacrylates, pentaerythritol tetraacrylates, dipentaerythritol dimethacrylates, dipentaerythritol trimethacrylates, dipentaerythritol tetramethacrylates, dipentaerythritol diacrylates, dipentaerythritol triacrylates, dipentaerythritol tetraacrylates, and divinylformamide.

### Claim 10 (depends on 7, 8, 9)

The method of any one of claims 7-9, wherein the sorbent is produced additionally utilizing one or both of at least one dispersing agent and at least one porogen.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the sorbent comprises a biocompatible and hemocompatible exterior coating that is covalently bound to the sorbent by free-radical grafting.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein said sorbent is administered prior to administration of supportive therapies.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein said sorbent is administered at the same time as administration of supportive therapies.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein said sorbent is administered following administration of supportive therapies.

### Claim 15 (depends on 12, 13, 14)

The method of anyone of claims 12-14, wherein the supportive therapy comprises administration of an immunotherapeutic agent selected from one or more of checkpoint inhibitors, monoclonal antibodies, and bi-specific T-cell engagers.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the administration of the sorbent reduces the severity of immunoparalysis.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the administration of the sorbent increases HLA-DR expression or function.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the administration of the sorbent reduces the damage to the body caused by the hyperinflammatory response, thereby decreasing the patient's risk of immunoparalysis.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any claims 1-11, wherein administration of the sorbent reduces T-cell or other immune cell exhaustion.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein administration of the sorbent results in removal of one or more of a) cytokine and b) soluble ligand from bodily/physiologic fluid of the subject.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein administration of the sorbent results in removal of inflammatory mediators.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein administration of the sorbent results in removal of one or more checkpoint inhibitor proteins and/or their soluble counterparts.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein administration of the sorbent results in partial or full restoration of T-cell or other immune cell function.

### Claim 24 (depends on 20)

The method of claim 20, wherein the soluble ligand is one or more of sPD-L1, sPD-L2, sMICA, SULBP2, sFasL, sCTLA-4, MHC class II, and sCD40L.

### Claim 25 (depends on 20)

The method of claim 20, wherein the cytokine comprises one or more of a member of interleukin, chemokine, interferon, lymphokine, tumor growth factor, or tumor necrosis factor family.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the sorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.

### Claim 27

A method of reducing sepsis and inflammation related T-cell dysfunction in a subject comprising treating the subject with a therapeutically effective amount of porous biocompatible polymer sorbent.

### Claim 28 (depends on 27)

The method of claim 27, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 3000 Å and a pore volume between about 0.5 cc/g to about 3 cc/g dry polymer.

### Claim 29 (depends on 27)

The method of claim 27, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5 cc/g dry polymer.

### Claim 30 (depends on 27, 28, 29)

The method of any one of claims 27-29, wherein the sorbent is administered extracorporeally.

### Claim 31 (depends on 27, 28, 29)

The method of any one of claims 27-29, wherein the sorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, orally, rectally, topically, or nasally.

### Claim 32 (depends on 29)

The method of claim 29, wherein the sorbent comprises a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 1,000 Å to 10,000 Å (pore diameter) of the sorbent is smaller than 2:1.

### Claim 33 (depends on 27, 28, 29, 30, 31, 32)

The method of any one of claims 27-32, wherein the sorbent is produced using at least one crosslinking agent and at least one monomer.

### Claim 34 (depends on 33)

The method of claim 33, wherein the monomer comprises divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide and mixtures thereof.

### Claim 35 (depends on 33, 34)

The method of claim 33 or claim 34, wherein the crosslinking agent comprises one or more or divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythrital dimethacrylates, pentaerythrital trimethacrylates, pentaerythrital, tetramethacrylates, pentaerythritol diacrylates, pentaerythritol triacrylates, pentaerythritol tetraacrylates, dipentaerythritol dimethacrylates, dipentaerythritol trimethacrylates, dipentaerythritol tetramethacrylates, dipentaerythritol diacrylates, dipentaerythritol triacrylates, dipentaerythritol tetraacrylates, and divinylformamide.

### Claim 36

A method of treating immunoparalysis in a subject in need thereof comprising contacting a physiologic fluid of the subject with a porous biocompatible polymer sorbent, wherein method removes inflammatory mediators, and/or anti-inflammatory mediators, and/or checkpoint proteins.

### Claim 37 (depends on 36)

The method of claim 36, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 3000 Å and a pore volume between about 0.5 cc/g to about 3 cc/g dry polymer.

### Claim 38 (depends on 36)

The method of claim 36, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5 cc/g dry polymer.

### Claim 39 (depends on 36, 37, 38)

The method of any one of claims 36-38, wherein the contacting comprises administering the sorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, orally, rectally, topically, or nasally.

### Claim 40 (depends on 36, 37, 38)

The method of any one of claims 36-38, wherein the contacting comprises administering the sorbent extracorporeally.

### Claim 41

A method of treating immunoparalysis in a subject in need thereof comprising administering a porous biocompatible polymer sorbent to the subject,
wherein the administering places the sorbent in contact with a physiologic fluid of the subject.

### Claim 42 (depends on 41)

The method of claim 41, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 3000 Å and a pore volume between about 0.5 cc/g to about 3 cc/g dry polymer.

### Claim 43 (depends on 41)

The method of claim 41, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5 cc/g dry polymer.

### Claim 44 (depends on 41, 42, 43)

The method of any one of claims 41-43, wherein the physiologic fluid is blood.

### Claim 45 (depends on 41, 42, 43, 44)

The method of any one of claims 41-44, wherein the sorbent is administered extracorporeally.

### Claim 46 (depends on 41, 42, 43, 44)

The method of any one of claims 41-44, wherein the sorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, orally, rectally, topically, or nasally.

### Claim 47

A method of treating immunoparalysis in a subject in need thereof comprising providing to the subject a porous biocompatible polymer sorbent.

### Claim 48 (depends on 47)

The method of claim 47, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 3000 Å and a pore volume between about 0.5 cc/g to about 3 cc/g dry polymer.

### Claim 49 (depends on 47)

The method of claim 47, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5 cc/g dry polymer.

### Claim 50 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the administration of the sorbent reduces the severity of immunoparalysis, immune suppression, or anergy.

### Claim 51 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the administration of the sorbent reduces the damage to the body caused by the hyperinflammatory response, thereby decreasing the patient's risk of immunoparalysis, immune suppression, or anergy.

### Claim 52 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein administration of the sorbent reduces T-cell exhaustion.

### Claim 53 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the sorbent results in removal of one or more of a) cytokine and b) soluble ligand from bodily/physiologic fluid of the subject.

### Claim 54 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the sorbent results in removal of inflammatory mediators.

### Claim 55 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the sorbent results in removal of checkpoint inhibitor proteins.

### Claim 56 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the sorbent results in results in partial or full restoration of T-cell function.

### Claim 57 (depends on 53)

The method of claim 53, wherein the soluble ligand is one or more of sPD-L1, sPD-L2, sMICA, SULBP2, sFasL, sCTLA-4, MHC class II, and sCD40L.

### Claim 58 (depends on 53)

The method of claim 53, wherein the cytokine comprises one or more of a member of interleukin, chemokine, interferon, lymphokine, tumor growth factor, or tumor necrosis factor family.

### Claim 59 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 47-58, wherein the sorbent is administered extracorporeally.

### Claim 60 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 47-58, wherein the sorbent is administered intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, orally, rectally, topically, or nasally.

### Claim 61

A method of treating sepsis and/or inflammation related T-cell or immune cell dysfunction in a subject in need thereof comprising contacting a physiologic fluid of the subject with a porous biocompatible polymer sorbent.

### Claim 62 (depends on 61)

The method of claim 61, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 3000 Å and a pore volume between about 0.5 cc/g to about 3 cc/g dry polymer.

### Claim 63 (depends on 61)

The method of claim 61, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5 cc/g dry polymer.

### Claim 64 (depends on 61, 62, 63)

The method of any one of claims 61-63, wherein the contacting comprises administering the sorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, orally, rectally, topically, or nasally.

### Claim 65 (depends on 61, 62, 63)

The method of any one of claims 61-63, wherein the contacting comprises administering the sorbent extracorporeally.

### Claim 66

A method of treating sepsis and/or inflammation related T-cell or other immune cell dysfunction in a subject in need thereof comprising administering a porous biocompatible polymer sorbent to the subject,
wherein the administering places the sorbent in contact with a physiologic fluid of the subject.

### Claim 67 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 47-66, wherein the physiologic fluid is blood.

### Claim 68

A method of treating sepsis and/or inflammation related T-cell dysfunction in a subject in need thereof comprising providing to the subject a porous biocompatible polymer sorbent.

### Claim 69 (depends on 66, 67, 68)

The method of any one of claims 66-68, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 3000 Å and a pore volume between about 0.5 cc/g to about 3 cc/g dry polymer.

### Claim 70 (depends on 66, 67, 68)

The method of any one of claims 66-68, wherein the sorbent comprises a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5 cc/g dry polymer.

### Claim 71 (depends on 66, 67, 68)

The method of any one of claims 66-68, wherein the contacting comprises administering the sorbent intravenously, intramuscularly, intratumorally, intradermally, intraperitoneally, subcutaneously, orally, rectally, topically, or nasally.

### Claim 72 (depends on 66, 67, 68)

The method of any one of claims 66-68, wherein the contacting comprises administering the sorbent extracorporeally.

### Claim 73 (depends on 70)

The method of claim 70, wherein the sorbent comprises a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 1,000 Å to 10,000 Å (pore diameter) of the sorbent is smaller than 2:1.

### Claim 74 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 66-73, wherein the sorbent is produced using at least one crosslinking agent and at least one monomer.

### Claim 75 (depends on 74)

The method of claim 74, wherein the monomer comprises one or more of divinylbenzene and ethylvinylbenzene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, and divinylformamide.

### Claim 76 (depends on 74, 75)

The method of claim 74 or claim 75, wherein the crosslinking agent comprises one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythrital dimethacrylates, pentaerythrital trimethacrylates, pentaerythrital, tetramethacrylates, pentaerythritol diacrylates, pentaerythritol triacrylates, pentaerythritol tetraacrylates, dipentaerythritol dimethacrylates, dipentaerythritol trimethacrylates, dipentaerythritol tetramethacrylates, dipentaerythritol diacrylates, dipentaerythritol triacrylates, dipentaerythritol tetraacrylates, and divinylformamide.

### Claim 77 (depends on 74, 75)

The method of claim 74 or claim 75, wherein the sorbent is produced additionally utilizing one or both of at least one dispersing agent and at least one porogen.

### Claim 78 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 66-73, wherein the sorbent comprises a biocompatible and hemocompatible exterior coating that is covalently bound to the sorbent by free-radical grafting.

### Claim 79 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 66-73, wherein said sorbent is administered prior to administration of supportive therapies.

### Claim 80 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 66-73, wherein said sorbent is administered at the same time as administration of supportive therapies.

### Claim 81 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 66-73, wherein said sorbent is administered following administration of supportive therapies.

### Claim 82 (depends on 81)

The method of claim 81, wherein the supportive therapy comprises administration of an immunotherapeutic agent selected from one or more of checkpoint inhibitors, monoclonal antibodies, and bi-specific T-cell engagers.

### Claim 83 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 66-73, wherein the sorbent comprises one or more residues of divinylbenzene and ethylvinylbenzene, styrene, and ethylstyrene monomers.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein administration for the sorbent results in decreased endothelial sequestration of leukocytes and/or increased presence of leukocytes to the area of infection or injury, and/or reduction in infection and/or improved healing.
